Perrigo Ready To Launch OTC Nasonex In 2022
As Company Completes Divestiture Of Latin American Business
Perrigo has received FDA approval for the OTC use of Nasonex 24-hour allergy (mometasone furoate monohydrate) 50mcg and plans to launch it later this year. The news comes after the company reported a healthy fourth quarter on the back of a strong rebound in the demand for cough/cold productsfresh from divesting its generic Rx prescription pharmaceutical business in 2021
You may also be interested in...
Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.
Perrigo has revealed plans to divest its OTC businesses in Brazil and Mexico to private equity firm Advent International, citing insufficient scale and weak margins.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.